DOCSLIB.ORG

Sulfonyl Ureas for Antidiabetic Therapy, an Overview for Glipizide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sulfonyl Ureas for Antidiabetic Therapy, an Overview for Glipizide International Journal of Pharmacy and Pharmaceutical Sciences ISSN- 0975-1491 Vol 2, Suppl 2, 2010 Review Article SULFONYL UREAS FOR ANTIDIABETIC THERAPY, AN OVERVIEW FOR GLIPIZIDE SHAMMI GOYAL1*, JITENDRA KUMAR RAI¹, R.K.NARANG¹, RAJESH K.S¹ 1 Nanotechnology Research Centre, Indo Soviet Friendship College of Pharmacy, Moga­142001, Punjab, India Email: [email protected] Received: 07 Jan 2010, Revised and Accepted: 24 Jan 2010 ABSTRACT Glipizide is a "second generation" sulfonylurea, an oral hypoglycemic agent for the management of non‐insulin dependent diabetes mellitus. Oral delivery of glipizide shows bioavailability problems and causes hypoglycemia with gastric disturbances. To overcome these problems, controlled release formulations as sustained release and controlled release tablets are available. Solubility of glipizide increases with increase in pH. Like any other sulfonylurea, glipizide appears to act principally by stimulating the insulin secretion from pancreatic beta‐cells. Glipizide overdose symptoms include low blood sugar. Keywords: Antidiabetic, Sulfonyl urea, Glipizide INTRODUCTION presumed that this effect is related to an alteration of the tissue plasma membrane, resulting in an increased number of insulin Glipizide is one of the most commonly prescribed drugs for receptors7. Data also suggest that glipizide improves glucose treatment of type II diabetes. It is an oral hypoglycemic drug from utilization not only by promoting pancreatic insulin release but also sulfonylurea group. It is active at very low doses, a characteristic by enhancing extra‐pancreatic availability of insulin and/or the feature of second generation sulfonylureas. Oral therapy with number of insulin receptors8. glipizide comprises problems of bioavailability fluctuations and may be associated with severe hypoglycemia and gastric disturbances. 4) Studies have demonstrated that during long‐term treatment with The physicochemical characteristics of glipizide has been given in sulfonylureas agents, plasma insulin levels either returned to Table 1. Although it is closely related to other sulfonylureas of the pretreatment values or actually decrease9. However, glipizide same therapeutic class such as glibenclamide, blood insulin and (unlike other sulfonylureas agents which result in decreased insulin glucose time courses differ. It also carries much lower risk of levels following long term treatment) maintains an elevated insulin hypoglycemia. secretory response (increased from 100% to 1500% above 7,10 DIABETES untreated values) for periods of 2 to 6 years or longer . These data indicate that glipizide causes a long‐term increase in glucose‐ Diabetes mellitus is a chronic metabolic disorder characterized by stimulated insulin secretion. high blood glucose concentrations (hyperglycemia) caused by insulin deficiency and it is often combined with insulin resistance3. 5) Glipizide has shown to potentiate chronic effects on insulin Non Insulin Dependent Diabetes Mellitus (NIDDM) represents a secretion7. At the same time, other studies utilizing glipizide for heterogeneous group comprising milder form of diabetes that occur periods of over 6 months have not reported tolerance to predominately in adults and a vast majority of diabetic patients hypoglycemic effects10. Stabilization of blood glucose levels were possess NIDDM4. The analytical parameters of glipizide which will reported for at least 4 years with glipizide therapy10. One study prove beneficial to researchers are shown in Table 2. Glipizide has reported that glipizide maintained control for up to 6 years in 70% been in extensive use to treat NIDDM and acts by increasing the of patients7 (cumulative secondary failure rate of approximately release of endogenous insulin as well as its peripheral effectiveness4; 30%). but it has been associated with severe and sometimes fatal 6) Studies by Brogden et al and other researchers has shown that hypoglycemia and gastric disturbances like nausea, vomiting, glipizide improved control of hyperglycemia in patients with poor heartburn, anorexia and increased appetite after oral therapy in results from other sulfonylureas5,10. However, improvement with normal doses. glipizide has been greater in patients who were well‐controlled on MECHANISM OF ACTION AND PHARMACOLOGY previous sulfonylureas therapy, compared to patients who responded poorly. 1) Glipizide is a "second generation" sulfonylureas, an oral hypoglycemic agent for the management of non‐insulin dependent 7) At the cellular level, sulfonylureas is known to bind to a diabetes mellitus (type II diabetes; maturity‐onset diabetes). On a sulfonylureas receptor on the pancreatic beta‐cell inhibiting the weight basis, glipizide is 100 times more potent than tolbutamide in adenosine triphosphate‐dependent potassium channel (K‐ATP). animal studies5. Glipizide has a more rapid onset of hypoglycemic Stabilization of potassium efflux causes depolarization and effect than glyburide (glibenclamide) and a shorter duration of activation of the L‐type calcium channel. Influx of calcium stimulates action5. insulin secretion. The effect of sulfonylureas is similar to that of glucose at the cellular level; however, sulfonylureas only stimulates 2) Glipizide reduces blood glucose by stimulating insulin secretion phase I (initial rapid peak) release of insulin and shows no effect on and altering insulin sensitivity; the drug causes a sustained increase phase II (prolonged insulin release). When sulfonylureas treatment in glucose‐stimulated insulin secretion in most patients during is initiated, insulin levels increase and plasma glucose levels prolonged therapy. gradually decrease. As the glucose levels decrease, insulin levels also 3) Like other drugs belonging to the class of sulfonylureas, glipizide decrease but still remain higher than pretreatment levels. appears to act principally by stimulating the insulin secretion from ADVANCES IN DELIVERY SYSTEMS pancreatic beta‐cells6. Glipizide is also reported to exert a major portion of its antidiabetic effect by altering the responsiveness of Some of the recent advancements incorporated for improved insulin‐sensitive tissues, such that the action of insulin is delivery of glipizide but yet to be released into the market is given potentiated5,7, an effect also postulated for chlorpropamide7. It is briefly below: 1 Int J Pharmacy Pharm Sci 1) Ashok V. Bhosale et al. has reported a formulation of glipizide 3) Mutalik, S. et al. has also performed pharmacological evaluation with beta cyclodextrin as a controlled release matrix tablet. of membrane moderated transdermal system of glipizide with The invitro evaluation shows promising results for the drug results which are acceptable for controlling diabetes13. where the release is for an extended period of time with 4) Jain, S, et al, have prepared and studied glipizide loaded constant levels (Ashok V. Bhosale et al.,2009). biodegradable nanoparticles and the influence of variables on 2) Mutalik, S. et al. has prepared and evaluated glipizide matrix transdermal systems for diabetes mellitus. Preclinical studies the formulation to show that it can be the future for diabetic are also completed for this formulation where the results are therapy14. adaptable for comfortable long term therapy13. Table 1: Physico characterstics of Glipizide² Sr. no. Description 1 Molecular formula C21H27N5O4S 2 Molecular weight 445.5 3 Physical state Powder (white) 4 Melting point 205 °C 5 Solubility Soluble Chloroform, dimethylformamide, Insoluble Water, ethanol Sparingly soluble Acetone 6 Dissociation constant pKa5.9 7 Partition coefficient Log P(octanol/water), 1.9 8 Colour test Mercurous Nitrate—black Table 2 Analytical parameters of Glipizide2 Particulars Thin layer chromatography System Rf value TA Rf 87 TB Rf 00 TC Rf 41 TE Rf 07 TL Rf 05 TAE Rf 86 High performance liquid chromatography System RI value HX 478 HY 423 HZ Retention time 4.5 min. HAA Retention time 17.6 min. Ultraviolet spectrum λmax 276 nm Infra‐red spectrum Principal peaks 1528,1690,1650,1159, 1032,900 cm−1 (KBr disk). Mass spectrum Principal ion at m/z 150,121,56,93,39,151,66,94. Table 3: Saturation Solubility of Glipizide at Different pH Sr. no. Medium Ph Saturation solubility(µg/mL) 1 2 1.1 2 4.4 1.3 3 5.22(DI water) 3.9 4 5.8 4.9 5 6.8 26.6 6 8 280.7 7 10 898.9 Fig. 1: pH solubility profile of Glipizide 2 Int J Pharmacy Pharm Sci The solubility is expected to increase by rise in pH. As given, Excretion glipizide shows increased solubility immediately above the pKa A) Through Kidney ‐ Renal Excretion is 63% to 89%. Only 3% to 9% values which is shown in Figure 1 and Table 3. It is recommended to of a dose is eliminated as unchanged drug; the majority of a dose is study the dissolution of glipizide at pH 6.8 buffer for experimental recovered as metabolites5. purposes. B) Other excreation is via feces,11% . CONVENTIONAL AND NOBLE FORMULATIONS OF GLIPIZIDE Elimination half­life Glipizide is available in market mainly in tablet form (2.5mg,5 mg, Elimination half‐life is 2 to 5 hours5,17.The half‐life did NOT differ 10mg). Some of different marketed brands available are shown in between middle‐aged (8.4 hours; mean=46.1 years) and elderly Table 4. patients (10.3 hours; mean=64.8 years). This study differs from earlier ones by using a 2‐ compartment model. The half‐life in obese PHARMACODYNAMICS/KINETICS versus nonobese patients was 5.4 hours and 6.7 hours, respectively, at steady state. This study differs from earlier ones by using a 2‐ Bioavailability compartment model.
Load more

Recommended publications
  • Metabolic-Hydroxy and Carboxy Functionalization of Alkyl Moieties in Drug Molecules: Prediction of Structure Influence and Pharmacologic Activity
    molecules Review Metabolic-Hydroxy and Carboxy Functionalization of Alkyl Moieties in Drug Molecules: Prediction of Structure Influence and Pharmacologic Activity Babiker M. El-Haj 1,* and Samrein B.M. Ahmed 2 1 Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, University of Science and Technology of Fujairah, Fufairah 00971, UAE 2 College of Medicine, Sharjah Institute for Medical Research, University of Sharjah, Sharjah 00971, UAE; [email protected] * Correspondence: [email protected] Received: 6 February 2020; Accepted: 7 April 2020; Published: 22 April 2020 Abstract: Alkyl moieties—open chain or cyclic, linear, or branched—are common in drug molecules. The hydrophobicity of alkyl moieties in drug molecules is modified by metabolic hydroxy functionalization via free-radical intermediates to give primary, secondary, or tertiary alcohols depending on the class of the substrate carbon. The hydroxymethyl groups resulting from the functionalization of methyl groups are mostly oxidized further to carboxyl groups to give carboxy metabolites. As observed from the surveyed cases in this review, hydroxy functionalization leads to loss, attenuation, or retention of pharmacologic activity with respect to the parent drug. On the other hand, carboxy functionalization leads to a loss of activity with the exception of only a few cases in which activity is retained. The exceptions are those groups in which the carboxy functionalization occurs at a position distant from a well-defined primary pharmacophore. Some hydroxy metabolites, which are equiactive with their parent drugs, have been developed into ester prodrugs while carboxy metabolites, which are equiactive to their parent drugs, have been developed into drugs as per se.
    [Show full text]
  • Actions of Glucagon-Like Peptide-1 on KATP Channel-Dependent and -Independent Effects of Glucose, Sulphonylureas and Nateglinide
    889 Actions of glucagon-like peptide-1 on KATP channel-dependent and -independent effects of glucose, sulphonylureas and nateglinide Neville H McClenaghan1, Peter R Flatt1 and Andrew J Ball1,2 1School of Biomedical Sciences, University of Ulster, Coleraine BT52 1SA, Northern Ireland, UK 2Chemicon International Inc., 28820 Single Oak Drive, Temecula, California 92590, USA (Requests for offprints should be addressed to A J Ball; Email: [email protected]) Abstract This study examined the effects of glucagon-like peptide-1 PKA and PKC downregulation, indicating that GLP-1 can (GLP-1) on insulin secretion alone and in combination with modulate KATP channel-independent insulin secretion by sulphonylureas or nateglinide, with particular attention to KATP protein kinase-dependent and -independent mechanisms. The channel-independent insulin secretion. In depolarised cells, synergistic insulin-releasing effects of combinatorial GLP-1 and GLP-1 significantly augmented glucose-induced KATP sulphonylurea/nateglinide were lost following PKA- or PKC- channel-independent insulin secretion in a glucose concen- desensitisation, despite GLP-1 retaining an insulin-releasing tration-dependent manner. GLP-1 similarly augmented the effect, demonstrating that GLP-1 can induce insulin release KATP channel-independent insulin-releasing effects of tolbuta- under conditions where sulphonylureas and nateglinide are no mide, glibenclamide or nateglinide. Downregulation of protein longer effective. Our results provide new insights into the kinase A (PKA)- or protein kinase C (PKC)-signalling pathways mechanisms of action of GLP-1, and further highlight the in culture revealed that the KATP channel-independent effects of promise of GLP-1 or similarly acting analogues alone or in sulphonylureas or nateglinide were critically dependent upon combination with sulphonylureas or meglitinide drugs in type 2 intact PKA and PKC signalling.
    [Show full text]
  • Optum Essential Health Benefits Enhanced Formulary PDL January
    PENICILLINS ketorolac tromethamineQL GENERIC mefenamic acid amoxicillin/clavulanate potassium nabumetone amoxicillin/clavulanate potassium ER naproxen January 2016 ampicillin naproxen sodium ampicillin sodium naproxen sodium CR ESSENTIAL HEALTH BENEFITS ampicillin-sulbactam naproxen sodium ER ENHANCED PREFERRED DRUG LIST nafcillin sodium naproxen DR The Optum Preferred Drug List is a guide identifying oxacillin sodium oxaprozin preferred brand-name medicines within select penicillin G potassium piroxicam therapeutic categories. The Preferred Drug List may piperacillin sodium/ tazobactam sulindac not include all drugs covered by your prescription sodium tolmetin sodium drug benefit. Generic medicines are available within many of the therapeutic categories listed, in addition piperacillin sodium/tazobactam Fenoprofen Calcium sodium to categories not listed, and should be considered Meclofenamate Sodium piperacillin/tazobactam as the first line of prescribing. Tolmetin Sodium Amoxicillin/Clavulanate Potassium LOW COST GENERIC PREFERRED For benefit coverage or restrictions please check indomethacin your benefit plan document(s). This listing is revised Augmentin meloxicam periodically as new drugs and new prescribing LOW COST GENERIC naproxen kit information becomes available. It is recommended amoxicillin that you bring this list of medications when you or a dicloxacillin sodium CARDIOVASCULAR covered family member sees a physician or other penicillin v potassium ACE-INHIBITORS healthcare provider. GENERIC QUINOLONES captopril ANTI-INFECTIVES
    [Show full text]
  • Management of Chronic Problems
    MANAGEMENT OF CHRONIC PROBLEMS INTERACTIONS BETWEEN ALCOHOL AND DRUGS A. Leary,* T. MacDonald† SUMMARY concerned. Alcohol may alter the effects of the drug; drug In western society alcohol consumption is common as is may change the effects of alcohol; or both may occur. the use of therapeutic drugs. It is not surprising therefore The interaction between alcohol and drug may be that concomitant use of these should occur frequently. The pharmacokinetic, with altered absorption, metabolism or consequences of this combination vary with the dose of elimination of the drug, alcohol or both.2 Alcohol may drug, the amount of alcohol taken, the mode of affect drug pharmacokinetics by altering gastric emptying administration and the pharmacological effects of the drug or liver metabolism. Drugs may affect alcohol kinetics by concerned. Interactions may be pharmacokinetic or altering gastric emptying or inhibiting gastric alcohol pharmacodynamic, and while coincidental use of alcohol dehydrogenase (ADH).3 This may lead to altered tissue may affect the metabolism or action of a drug, a drug may concentrations of one or both agents, with resultant toxicity. equally affect the metabolism or action of alcohol. Alcohol- The results of concomitant use may also be principally drug interactions may differ with acute and chronic alcohol pharmacodynamic, with combined alcohol and drug effects ingestion, particularly where toxicity is due to a metabolite occurring at the receptor level without important changes rather than the parent drug. There is both inter- and intra- in plasma concentration of either. Some interactions have individual variation in the response to concomitant drug both kinetic and dynamic components and, where this is and alcohol use.
    [Show full text]
  • Eslicarbazepine Acetate Longer Procedure No
    European Medicines Agency London, 19 February 2009 Doc. Ref.: EMEA/135697/2009 CHMP ASSESSMENT REPORT FOR authorised Exalief International Nonproprietary Name: eslicarbazepine acetate longer Procedure No. EMEA/H/C/000987 no Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. product Medicinal 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: [email protected] http://www.emea.europa.eu TABLE OF CONTENTS 1. BACKGROUND INFORMATION ON THE PROCEDURE........................................... 3 1.1. Submission of the dossier ...................................................................................................... 3 1.2. Steps taken for the assessment of the product..................................................................... 3 2. SCIENTIFIC DISCUSSION................................................................................................. 4 2.1. Introduction............................................................................................................................ 4 2.2. Quality aspects ....................................................................................................................... 5 2.3. Non-clinical aspects................................................................................................................ 8 2.4. Clinical aspects....................................................................................................................
    [Show full text]
  • Enhancement of Dissolution and Oral Bioavailability of Gliquidone with Hydroxy Propyl-Β-Cyclodextrin
    ORIGINAL ARTICLES Pharmacology Division, Indian Institute of Chemical Technology, Hyderabad, India Enhancement of dissolution and oral bioavailability of gliquidone with hydroxy propyl-b-cyclodextrin S. Sridevi, A. S. Chauhan, K. B. Chalasani, A. K. Jain, P. V. Diwan Received November 15, 2002, accepted May 5, 2003 Dr. Prakash V. Diwan, Pharmacology Division, Indian Institute of Chemical Technology, Hyderabad – 500 007 A.P., India [email protected] Pharmazie 58: 807–810 (2003) The virtual insolubility of gliquidone in water results in poor wettability and dissolution characteristics, which may lead to a variation in bioavailability. To improve these characteristics of gliquidone, binary systems with hydroxypropyl-b-cyclodextrin (HP-b-CD) were prepared by classical methods such as physical mixing, kneading, co-evaporation and co-lyophilization. The solid state interaction between the drug and HP-b-CD was assessed by evaluating the binary systems with X-ray diffraction, differen- tial scanning calorimetry and IR- spectroscopy. The results establish the molecular encapsulation and amorphization of gliquidone. The phase solubility profile of gliquidone in aqueous HP-b-CD vehicle À1 resulted in an AL type curve with a stability constant of 1625 M . The dissolution rate of binary sys- tems was greater than that of pure drug and was significantly higher in the case of co-lyophilized and co-evaporated systems. Upon oral administration, [AUC]0-a was significantly higher in case of co-lyo- philized (2 times) and co-evaporated systems (1.5 times) compared to pure drug suspension while other binary systems showed only a marginal improvement. The study ascertained the utility of HP-b- CD in enhancing the oral bioavailability of gliquidone, and points towards a strong influence of the preparation method on the physicochemical properties.
    [Show full text]
  • Medication Choice Diabetes
    Weight Change Low Blood Sugar Blood Sugar Considerations (Hypoglycemia) Blood(A1c Reduction) Sugar Weight Change Low Blood Sugar (A1c Reduction) Considerations (Hypoglycemia) Metformin Metformin Metformin 1 – 2% Metformin In the rst few weeks after starting Metformin, patients may have some nausea, indigestion or diarrhea. None No Severe Risk Minor = 0 – 1% Insulin There are no other side effects associated with Insulin. Insulin Insulin Insulin Unlimited % Pioglitazone 4 to 6 lb. gain Over time, 10 in 100 people may have fluid retention Severe = 1 – 3% Minor = 30 – 40% (edema) while taking the drug. For some it may be as little as ankle swelling. For others, fluid may build up Pioglitazone 1% in the lungs making it difficult to breathe. This may Pioglitazone Pioglitazone resolve after you stop taking the drug. 10 in 100 people at risk of bone fractures who use this drug will have More than 2 to 6 lb. gain a bone fracture in the next 10 years. There appears to No Severe Risk Minor = 1 – 2% be a slight increase in the risk of bladder cancer with Liraglutide/ 0.5 – 1% this drug. Liraglutide/Exenatide Liraglutide/Exenatide Exenatide Liraglutide/Exenatide Some patients may have nausea or diarrhea. In some 3 to 6 lb. loss cases, the nausea may be severe enough that a patient No Severe Risk Minor = 0 – 1% has to stop taking the drug. There are reports of pain in the abdomen that may be caused by inammation Sulfonylureas Sulfonylureas Sulfonylureas 1 – 2% of the pancreas with these agents. Glipizide, Glimepiride, Glyburide Glipizide, Glimepiride, Glyburide Glipizide, Glimepiride, Glyburide Sulfonylureas 2 to 3 lb.
    [Show full text]
  • Sulfonylurea Review
    Human Journals Review Article February 2018 Vol.:11, Issue:3 © All rights are reserved by Farah Yousef et al. Sulfonylurea Review Keywords: Type II diabetes, Sulfonylurea, Glimipiride, Glybu- ride, Structure Activity Relationship. ABSTRACT Farah Yousef*1, Oussama Mansour2, Jehad Herbali3 Diabetes Mellitus is a chronic disease represented with high 1 Ph.D. candidate in pharmaceutical sciences, Damas- glucose blood levels. Although sulfonylurea compounds are the cus University, Damascus, Syria. second preferred drug to treat Type II Diabetes (TYIID), they are still the most used agents due to their lower cost and as a 2 Assistant Professor in pharmaceutical chimestry, Ti- mono-dosing. Literature divides these compounds according to st nd rd shreen University, Lattakia, Syria their discovery into 1 , 2 , 3 generations. However, only six sulfonylurea compounds are now available for use in the United 3 Assistant Professor in pharmaceutical chimestry, Da- States: Chlorpropamide, Glimepiride, Glipizide, Glyburide, mascus University, Damascus, Syria. Tolazamide, and Tolbutamide. They function by increasing Submission: 24 January 2018 insulin secretion from pancreatic beta cells. Their main active site is ATP sensitive potassium ion channels; Kir 6.2\SUR1; Accepted: 29 January 2018 Published: 28 February 2018 Potassium Inward Rectifier ion channel 6.2\ Sulfonylurea re- ceptor 1. They are sulfonamide derivatives. However, research- ers have declared that sulfonylurea moiety is not the only one responsible for this group efficacy. It has been known that sud- den and acute hypoglycemia incidences and weight gain are the www.ijppr.humanjournals.com two most common adverse effects TYIID the patient might face during treatment with sulfonylurea agents. This review indi- cates the historical development of sulfonylurea and the differ- ences among this group members.
    [Show full text]
  • Association Between Serious Hypoglycemia and Calcium-Channel Blockers Used Concomitantly with Insulin Secretagogues
    Research Letter | Diabetes and Endocrinology Association Between Serious Hypoglycemia and Calcium-Channel Blockers Used Concomitantly With Insulin Secretagogues Young Hee Nam, PhD; Colleen M. Brensinger, MS; Warren B. Bilker, PhD; James H. Flory, MD; Charles E. Leonard, MSCE, PharmD; Sean Hennessy, PhD, PharmD Introduction + Supplemental content Serious hypoglycemia is a major, potentially fatal adverse event caused by insulin secretagogues.1 Author affiliations and article information are Previous case reports suggested that calcium-channel blockers (CCBs) might reduce the risk of listed at the end of this article. serious hypoglycemia in patients with hyperinsulinemic hypoglycemia.2,3 However, the association of serious hypoglycemia and CCBs used with insulin secretagogues has remained unclear. Because insulin secretion by the pancreas is mediated by calcium influx in beta cells through calcium channels,4 we conducted a population-based observational study on the hypothesis that concomitant use of CCBs may be associated with reduced rates of serious hypoglycemia in insulin secretagogue users. Methods This self-controlled case series study was approved by the institutional review board of the University of Pennsylvania, which waived the requirement for informed consent because the use or disclosure of the protected health information involved no more than minimal risk to the privacy of individuals, and the research could not practicably be conducted without the waiver or alteration and without access to and use of the protected health information. We followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline. We used claims data from the Medicaid programs of 5 US states (California, Florida, New York, Ohio, and Pennsylvania, encompassing more than a third of the nationwide Medicaid population), supplemented with Medicare claims for dual enrollees, from January 1, 1999, to December 31, 2011, and used the self- controlled case series design.
    [Show full text]
  • Sulfonylureas
    Therapeutic Class Overview Sulfonylureas INTRODUCTION In the United States (US), diabetes mellitus affects more than 30 million people and is the 7th leading cause of death (Centers for Disease Control and Prevention [CDC] 2018). Type 2 diabetes mellitus (T2DM) is the most common form of diabetes and is characterized by elevated fasting and postprandial glucose concentrations (American Diabetes Association [ADA] 2019[a]). It is a chronic illness that requires continuing medical care and ongoing patient self-management education and support to prevent acute complications and to reduce the risk of long-term complications (ADA 2019[b]). ○ Complications of T2DM include hypertension, heart disease, stroke, vision loss, nephropathy, and neuropathy (ADA 2019[a]). In addition to dietary and lifestyle management, T2DM can be treated with insulin, one or more oral medications, or a combination of both. Many patients with T2DM will require combination therapy (Garber et al 2019). Classes of oral medications for the management of blood glucose levels in patients with T2DM focus on increasing insulin secretion, increasing insulin responsiveness, or both, decreasing the rate of carbohydrate absorption, decreasing the rate of hepatic glucose production, decreasing the rate of glucagon secretion, and blocking glucose reabsorption by the kidney (Garber et al 2019). Pharmacologic options for T2DM include sulfonylureas (SFUs), biguanides, thiazolidinediones (TZDs), meglitinides, alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogs, amylinomimetics, sodium-glucose cotransporter 2 (SGLT2) inhibitors, combination products, and insulin (Garber et al 2019). SFUs are the oldest of the oral antidiabetic medications, and all agents are available generically. The SFUs can be divided into 2 categories: first-generation and second-generation.
    [Show full text]
  • Flufenamic Acid # # Keke Zhang, Noalle Fellah, Vilmalí Lopez-Mej́ Ías, and Michael D
    pubs.acs.org/crystal Communication Polymorphic Phase Transformation Pathways under Nanoconfinement: Flufenamic Acid # # Keke Zhang, Noalle Fellah, Vilmalí Lopez-Mej́ ías, and Michael D. Ward* Cite This: Cryst. Growth Des. 2020, 20, 7098−7103 Read Online ACCESS Metrics & More Article Recommendations *sı Supporting Information ABSTRACT: Flufenamic acid (FFA) is a highly polymorphic com- pound, with nine forms to date. When melt crystallization was performed under nanoscale confinement in controlled pore glass (CPG), the formation of the extremely unstable FFA form VIII was favored. Under confinement, form VIII was sufficiently stable to allow the measurement of its melting point, which decreased with decreasing pore size in accord with the Gibbs−Thomson relationship, enabling determination of the otherwise elusive melting point of the bulk form. Moreover, the transformation pathways among the various polymorphs depended on pore size, proceeding as form VIII → form II → form I for nanocrystals embedded in 30−50-nm diameter pores, and form VIII → form IV → form III in 100−200 nm pores. In contrast, form VIII converts directly to form III in the bulk. Whereas previous reports have demonstrated that nanoconfinement can alter (thermodynamic) polymorph stability rankings, these results illustrate that nanoscale confinement can arrest and alter phase transformations kinetics such that otherwise hidden pathways can be observed. olymorphism in solid-state materials can be a double- intersect.11 This has been most apparent in the observation P edged sword.
    [Show full text]
  • New Therapeutic Agents Marketed in 2014: Part 1 Daniel A
    CPE New therapeutic agents marketed in 2014: Part 1 Daniel A. Hussar Objective: To provide information regarding the most important properties of Daniel A. Hussar, PhD, is Remington Professor of Pharmacy, Philadelphia College new therapeutic agents that have been marketed in 2014. of Pharmacy, University of the Sciences in Data sources: Product labeling supplemented selectively with published studies Philadelphia. and drug information reference sources. Development: This home-study CPE activity Data synthesis: Seven new therapeutic agents that were marketed in the United was developed by the American Pharmacists States in early 2014 are considered in this first of a four-part series: umeclidinium Association. bromide/vilanterol trifenatate, perampanel, eslicarbazepine acetate, apremilast, dapagliflozin propanediol, avanafil, and bazedoxifene/conjugated estrogens. In- dications and information on dosage and administration for these agents are re- viewed, as are the most important pharmacokinetic properties, drug interactions, and other precautions. Practical considerations for use of these new agents are also discussed. When possible, properties of the new drugs are compared with those of older agents marketed for the same indications. Conclusion: Umeclidinium/vilanterol is the first combination formulation for oral inhalation to include both a long-acting muscarinic antagonist and a long-acting beta-2-adrenergic agonist for the maintenance treatment of patients with chronic ob- structive pulmonary disease. Both perampanel and eslicarbazepine have been ap- proved as adjunctive treatment for patients with partial-onset seizures. Perampanel has a unique mechanism of action whereas eslicarbazepine has properties that are most similar to those of oxcarbazepine. Apremilast is indicated for the treatment of patients with active psoriatic arthritis and is effective following oral administra- tion.
    [Show full text]